Skip to main content
Premium Trial:

Request an Annual Quote

BG Medicine Offering $2.1M in Stocks, Warrants

NEW YORK (GenomeWeb News) – BG Medicine announced today a public offering of units comprising its common stock and warrants that is expected to bring in net proceeds of $2.1 million.

The Waltham, Massachusetts-based firm is offering 2,315,654 Series A units each consisting of one share of common stock and one half of a warrant to purchase one share of common stock at $1 per Series A unit.

BG Medicine is also offering 184,346 Series B units for $1.00 per unit to investors whose purchase of additional Series A units would result in them owning more than 9.99 percent of the company's outstanding common stock following completion of the offering.

The company said it plans to use the funds to support the US launch of the first automated version of its galectin-3 cardiovascular biomarker test, the expansion of clinical claims and indications for galectin-3, and for other general corporate purposes.

Roth Capital Partners is acting as lead manager for the offering.

BG Medicine stock was down 40 percent to $.90 in morning trading on the Nasdaq.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.